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background:  Thrombocytopenia is common in certain types of cancer. Research data and guidelines about PCI in this subgroup of 
patients is scarce as cancer patients have been excluded from all major PCI clinical trials.
methods: Between 11/2009 and 11/2013 a total of 1,517 consecutive cancer patients underwent cardiac catheterization at MD Anderson 
Center. Hemorrhagic complications were defined according to Bleeding Academic Research Consortium (BARC) criteria grading scale of 
bleeding severity.
results:  Out of the 1,517 treated patients 190 (13.5%) had thrombocytopenia (platelets≤100K/mm3) and underwent 198 cardiac 
catheterization procedures. Mean platelet count was 48.8K/ mm3 with the lowest being 5K/mm3. Procedures were performed successfully 
in all patients (100%) utilizing both femoral and radial access. Out of 92 patients with thrombocytopenia and ACS, 36 (39%) underwent 
PCI requiring higher ACT and dual antiplatelet therapy (DAPT). Four type 1 (2%) and one type 3a (0.5%) (BARC criteria) bleeding 
complications were identified. None of the patients on DAPT had grade 3 or 4 WHO bleeding during therapy. No cardiovascular related 
deaths occurred.
Conclusion:  Chronic thrombocytopenia was not associated with significantly increased major bleeding or major adverse cardiovascular 
events in a tertiary center with expertise in high-risk interventions. An invasive approach should be considered in cancer patients with 
chronic thrombocytopenia.
Cardiac Catheterization in Cancer Patients with Thrombocytopenia (198 procedures)
Indication Acute Coronary Syndrome 92 (46.5%)
Cardiomyopathy 106 (53.5%)
Arterial Access Femoral 185 (93.4%)
Transradial 13 (6.6%)
Platelet Count (K/mm3) <25 70 (35%)
25-49 49 (25%)
50-75 43 (22%)
76-100 36 (18%)
Bleeding Complications (BARC criteria) Type 1 4 (2%)
Type 3a 1 (0.5%)
